Data from FDA - Curated by EPG Health - Last updated 06 September 2018

Indication(s)

1 INDICATIONS AND USAGE JETREA® is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. JETREA is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. (1)

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Nephropathic Cystinosis

Nephropathic Cystinosis

Learn about the use of cystine-depleting pharmacotherapy and other supportive care measures for patients with nephropathic cystinosis.

+ 2 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Related Content

Advisory information

contraindications
4 CONTRAINDICATIONS None None. (4)
Adverse reactions
6 ADVERSE REACTIONS The following adverse reactions are described below and elsewhere in the labeling: Decreased Vision [see Warnings and Precautions (5.1)] Intravitreal Injection Procedure Associated Effects [see Warnings and Precautions (5.2) and Dosage And Administration (2.4) ] Potential for Lens Subluxation [see Warnings and Precautions (5.3)] Retinal Breaks [see Warnings and Precautions (5.4) and Dosage And Administration (2.4)] Dyschromatopsia [see Warnings and Precautions (5.5)] The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact ThromboGenics Inc. at 1-855-253-7396 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice. Approximately 800 patients have been treated with an intravitreal injection of JETREA. Of these, 465 patients received an intravitreal injection of ocriplasmin 0.125 mg (187 patients received vehicle) in the 2 vehicle-controlled studies (Study 1 and Study 2). The most common adverse reactions (incidence 5% - 20% listed in descending order of frequency) in the vehicle-controlled clinical studies were: vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema. Less common adverse reactions observed in the studies at a frequency of < 5% in patients treated with JETREA included macular edema, increased intraocular pressure, anterior chamber cell, photophobia, vitreous detachment, ocular discomfort, iritis, cataract, dry eye, metamorphopsia, pupillary reflex impaired, conjunctival hyperemia, retinal degeneration, and visual symptoms perceived in the contralateral eye. Dyschromatopsia was reported in 2% of patients injected with JETREA, with the majority of cases reported from two uncontrolled clinical studies. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease). 6.2 Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. Immunogenicity for this product has not been evaluated. 6.3 Postmarketing Experience Night blindness has been identified during post-approval use of JETREA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Usage information

Dosing and administration
2 DOSAGE AND ADMINISTRATION For single use ophthalmic intravitreal injection only. (2.1) No dilution required. (2.1) The recommended dose is 0.125 mg (0.1 mL) administered by intravitreal injection to the affected eye once as a single dose. (2.2) 2.1 General Dosing Information For single-use ophthalmic intravitreal injection only. JETREA must only be administered by a qualified physician. This formulation of JETREA does not require dilution. 2.2 Dosing The recommended dose is 0.125 mg (0.1 mL of the solution) administered by intravitreal injection to the affected eye once as a single dose. 2.3 Preparation for Administration To prepare JETREA for intravitreal injection, adhere to the following instructions: Remove the vial (1.25 mg/mL corresponding to 0.375 mg ocriplasmin) from the freezer and allow to thaw at room temperature (within a few minutes). Use JETREA immediately after thawing. Unopened vials in the original carton protected from light can be stored up to 8 hours when stored below 77°F (25°C). Do not refreeze a vial once it has been thawed. Once completely thawed, remove the protective polypropylene blue flip-off cap from the vial (see Figure 1). Figure 1: The top of the vial should be disinfected with an alcohol wipe (see Figure 2) . Figure 2: Visually inspect the vial for particulate matter. Only a clear, colorless solution without visible particles should be used. Using aseptic technique, withdraw all of the solution using a sterile #19 gauge needle (slightly tilt the vial to ease withdrawal) and discard the needle after withdrawal of the vial contents (see Figure 3 ). Do not use this needle for the intravitreal injection. Figure 3: Replace the needle with a sterile #30 gauge needle, carefully expel the air bubbles and excess drug from the syringe and adjust the dose to the 0.1 mL mark on the syringe (corresponding to 0.125 mg ocriplasmin) (see Figure 4 ) . Figure 4: THE SOLUTION SHOULD BE USED IMMEDIATELY AS IT CONTAINS NO PRESERVATIVES. Discard the vial and any unused portion of the solution after single use. Figure 1 Figure 2 Figure 3 Figure 4 2.4 Administration and Monitoring The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad spectrum microbiocide should be administered according to standard medical practice. The injection needle should be inserted 3.5 - 4.0 mm posterior to the limbus aiming towards the center of the vitreous cavity, avoiding the horizontal meridian. The injection volume of 0.1 mL is then delivered into the mid-vitreous. Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available. Following intravitreal injection, patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurred or decreased vision) without delay [see Patient Counseling Information (17)] . Each vial should only be used to provide a single injection for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, and injection needles should be changed before JETREA is administered to the other eye, however, treatment with JETREA in the other eye is not recommended within 7 days of the initial injection in order to monitor the post-injection course including the potential for decreased vision in the injected eye. Repeated administration of JETREA in the same eye is not recommended [see Nonclinical Toxicology (13.2)]. After injection, any unused product must be discarded. No special dosage modification is required for any of the populations that have been studied (e.g. gender, elderly).
Use in special populations
8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Teratogenic Effects Pregnancy Category C. Animal reproduction studies have not been conducted with ocriplasmin. There are no adequate and well-controlled studies of ocriplasmin in pregnant women. It is not known whether ocriplasmin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The systemic exposure to ocriplasmin is expected to be low after intravitreal injection of a single 0.125 mg dose. Assuming 100% systemic absorption (and a plasma volume of 2700 mL), the estimated plasma concentration is 46 ng/mL. JETREA should be given to a pregnant woman only if clearly needed. 8.3 Nursing Mothers It is not known whether ocriplasmin is excreted in human milk. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when JETREA is administered to a nursing woman. 8.4 Pediatric Use The use of JETREA in pediatric patients is not recommended. A single center, randomized, placebo controlled, double masked clinical study to investigate the safety and efficacy of a single intravitreal injection of 0.175 mg ocriplasmin in pediatric subjects as an adjunct to vitrectomy was conducted in 24 eyes of 22 patients. There were no statistical or clinical differences between groups for the induction of total macular posterior vitreous detachment (PVD), any of the secondary endpoints or adverse events. 8.5 Geriatric Use In the clinical studies, 384 and 145 patients were ≥ 65 years and of these 192 and 73 patients were ≥ 75 years in the JETREA and vehicle groups respectively. No significant differences in efficacy or safety were seen with increasing age in these studies.
Pregnancy and lactation
8.3 Nursing Mothers It is not known whether ocriplasmin is excreted in human milk. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when JETREA is administered to a nursing woman.

More information

Category Value
Authorisation number BLA125422
Agency product number 7V6HE3DM5A
Orphan designation No
Product NDC 24856-002
Date Last Revised 18-05-2017
Type HUMAN PRESCRIPTION DRUG
Marketing authorisation holder ThromboGenics Inc.